SUMMARY To assess the relative influence of central pharmacodynamic and peripheral pharmacokinetic factors on the duration of motor response to levodopa, the relationship between motor function and plasma levodopa levels was studied in 31 Parkinsonian patients. Duration of benefit from single levodopa doses while fasting depended on the degree to which the plasma levodopa level had declined over four hours; wearing off occurred when the plasma levodopa level had fallen to approximately 50% of peak concentration, irrespective of the duration of the motor response. Whilst the amplitude ofmotor response to levodopa is likely to be modified by alternations in dopamine receptor stimulation and sensitivity as the disease progresses, it is proposed that the duration of response is primarily determined by levodopa peripheral pharmacokinetics rather than by central pharmacodynamic factors associated with dopamine storage capacity.
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Motor fluctuations eventually develop in most patients with Parkinson's disease who have received sustained levodopa treatment.' 2 It has been suggested that the evolution of motor oscillations occurs as a result of progressive reduction in duration of response to levodopa doses.3 Previous studies have shown that the peripheral pharmacokinetic handling of levodopa is similar in patients with long and short duration of levodopa therapy,4 so it seems unlikely that changes in levodopa peripheral pharmacokinetics in individual patients could account for the development of fluctuations. Cerebral pharmacodynamic factors have therefore been considered to determine the duration of response to levodopa. One postulated mechanism is that the duration of the motor response (MR) to a dose of levodopa depends on the capacity of surviving nigro-striatal terminals to store dopamine after it has been synthesised from exogenous levodopa;5 thus progressive reduction in dopamine storage capacity that accompanies the degeneration of the dopaminergic nigro-striatal pathway is held to be responsible for declining duration of effectiveness of levodopa doses.
Wearing off of dose responses has been shown to occur when the plasma levodopa level is declining. dopa treatment for up to 5 years was 6-4 compared with 14-5 for cases treated with levodopa for greater than 10 years (p < 0-01) (fig 3) . By contrast, time to wearing off of MR showed overlap among patients treated with levodopa for different periods and the small reduction in mean time in patients on levodopa for greater than 10 years compared with less than 5 years was not significant (fig 4) . MR duration was also analysed in relation to modified Webster score MR amplitude. Time to wearing off of MR was 5-2 hours for MR amplitude 0-8 (8 patients), 4-2 hours for amplitude 9-16 (14 patients) and 4-6 hours for amplitude 17-24 (seven patients) (0-5 < 0-1 for difference between high and low MR amplitude groups). Figure 5 illustrates the relationship between the ratio of levodopa level at four hours post-dose to peak levodopa level and the time to wearing off. There is a strong correlation between these two variables (r = 0-73, p < 0-01), suggesting that plasma levodopa is more sustained four hours after dosing with respect to peak level in patients with more sustained MR. Individual correlation coefficients for the components ofthe levodopa level ratio were -0-41 for time to wearing offversus peak levodopa level, and + 0-56 for time to wearing off versus levodopa level at four hours post-dose. Figure 6 shows values for the ratio of levodopa level at the time of wearing off to peak level. No significant correlation was present between this ratio and the time to wearing off, suggesting that a similar degree of decline of levodopa level to approximately 50% of peak level resulted in wearing offof MR irrespective of time from dose to wearing off. Individual correlation coefficients were -0-42 for time to wearing off versus peak levodopa level and -0-23 for time to wearing off versus levodopa level at wearing off.
Comparison of pharmacokinetic parameters of peak levodopa level (Cmax), time to peak levodopa level (Tmax) and ratio of4 hour to peak levels failed to show significant difference between patients taking levodopa for long and short periods (table 2). Comparison of pharmacokinetic parameters confirms previous observations that peripheral levodopa pharmacokinetics are similar irrespective of duration of disease or of levodopa therapy, and presumably remain unchanged in individual patients. The hypothesis that contracting MR time is a cause of oscillating motor function5 predicts that, following levodopa doses, progressively less decline in blood levodopa level will result in wearing off of motor response as oscillations become increasingly apparent. However, our results suggest that the degree of fall of blood levodopa level from peak level that leads to wearing off of MR appears to be similar irrespective of time from dose to wearing off. The time course of motor responses mirror the profile of blood levodopa levels and differences in duration of response are explained by differences in the degree of decline in blood levodopa level over 4 hours. This study has not explored the role of other factors which may influence motor oscillations such as protein intake and the effects of multiple doses. Nevertheless it did not provide evidence that central pharmacodynamic factors associated with striatal dopamine storage capacity cause less sustained MR for a given plasma levodopa level in patients with shorter duration of responses.
Evidence from positron emission neuroimaging suggest that administration of levodopa to Parkinsonian patients results in less prolonged striatal accumulation of dopamine compared with normal subjects.9
This probably reflects differences in accumulation of dopamine in intraneuronal vesicles of nigro-striatal Kempster, Frankel, Bovingdon, Webster, Lees, Stern terminals and has been taken as support for the hypothesis that striatal dopamine storage capacity is an important determinant of the duration of MR. However, the clinical effects of administered levodopa may not be dependent on vesicular storage and synaptic release of dopamine by surviving nigrostriatal neurons. Aromatic amino acid decarboxylase, the enzyme which converts levodopa to dopamine, is widely distributed in brain tissue and animal studies suggest that significant amounts of levodopa can be synthesised outside dopaminergic neurons.'" Release of dopamine by nigro-striatal neurons may also occur independently of vesicular storage and synaptic release, with dopamine diffusing out of striatal terminals after synthesis." Our observations that MR time correlates with the peripheral levodopa level profile are consistent with the notion that exogenous levodopa does not rely on synaptic storage and release of dopamine by nigro-striatal terminals to produce its clinical effects. When factors such as competition for neutral amino acid transport across the blood-brain barrier are minimised, the level of extracellular dopamine in the vicinity of striatal dopamine receptor sites may vary in time with blood levodopa levels. Further clinical evidence that dopamine storage capacity is not of major importance in determining the time course of levodopa motor responses comes from observations in patients with asymmetry of Parkinsonian motor deficits attributed to asymmetry of nigral cell degeneration. Despite presumed asymmetry of dopamine storage capacity, no asymmetry in duration of MR to levodopa doses occurs.'2
The evolution of motor oscillations would be best examined by longitudinal studies in individual patients over many years. Nevertheless it is proposed that levodopa peripheral pharmacokinetics and duration of MR remain unaltered as the disease progresses but that increasing amplitude ofmotor responses leads to clinically apparent fluctuations. Increasing off phase disability due to progressive nigro-striatal degeneration and changes in the central pharmacodynamics of dopamine receptor stimulation may both contribute to changes in response amplitude. However, the duration of levodopa MR is essentially determined by peripheral pharmacokinetic factors.
